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Outpatient parenteral antimicrobial therapy (OPAT) is a method for delivering intravenous 
antimicrobials in outpatient settings and is an alternative to inpatient care [1-2]. Although this 
approach is not commonly used in children primarily due to the potential risks, it is gradually 
gaining importance and has been used for the treatment of a number of infections. Research 
has shown that OPAT leads to a reduction in admissions, a reduction in length of stay in 
hospitals and is cost saving compared to inpatient care [3-6]. It has also been shown that 
OPAT reduces the risk of hospital acquired infections which is a contributory factor to 
antimicrobial resistance [7].   
A study by Ibrahim and colleagues published in The Lancet Infectious Diseases [8] assessed 
the cost-effectiveness of OPAT compared to standard hospital care for the intravenous 
treatment of moderate/severe cellulitis in children. The analysis assumed a societal 
perspective and was conducted alongside the Cellulitis at Home Or Inpatient in Children 
from Emergency (CHOICE) randomised controlled trial [9]. To the best of our knowledge, 
this is the first study to investigate the cost-effectiveness of OPAT for children with cellulitis. 
The study showed that OPAT is less costly (mean hospital cost difference per patient episode 
of -$1809; 95% CI -1324 to -2295 and mean family cost difference per patient episode of       
-$410; 95% CI -312 to -508), more effective (quality adjusted life year (QALY) difference of 
0·0006; 95% CI 0·0004 to 0·0008) and cost-effective compared to standard hospital care. The 
implication of the results suggests that using OPAT to deliver intravenous antimicrobials in 
outpatient settings should be adopted more widely for the management of children with 
moderate/severe cellulitis. However, a possible limitation of the study relates to the artificial 
nature of the single site trial which limits the generalisability and external validity of the 
findings. The authors however attempted to address this using sensitivity analyses.  
 
A fundamental issue associated with economic evaluation studies that consider children 
relates to how health related quality of life is measured. The study by Ibrahim and colleagues 
included participants aged between 6 months to 18 years and used the Child Health Utility 
9D (CHU9D) questionnaire [10] to derive QALYs. The advantage of using the CHU9D for 
economic evaluations is that it is preference-based and can be used to generate QALYs. 
However, this measure may not be valid for the full range of participants included in the 
study, such as those below 5 years. It is therefore suggested that economic evaluations of this 
sort consider other health-related quality of life measures in addition to the CHU9D. In 
addition, the study understandably used proxy completion for younger children (below 6 
years) and self-completion for older children (above 6 years) which raises questions relating 
to consistency and proxy bias [11].  
The importance of including the cost of antimicrobial resistance in economic evaluation 
studies that consider antibiotic use has been highlighted by a few studies [12-13], and 
although there is a lot of uncertainty and practical issues associated with the estimation of this 
cost, it is important that studies such as that by Ibrahim and colleagues are encouraged to 
account for the cost of antimicrobial resistance within economic evaluations. Doing so will 
ensure that there is an assessment of the impact of the different treatment pathways on 
antimicrobial resistance and also ensure that sub-optimal policy recommendations are 
avoided. This would however require additional research into how the costs associated with 
antimicrobial resistance are estimated and included within economic evaluations.   
Whilst the findings by Ibrahim and colleagues represent an important first step in determining 
the cost-effectiveness of OPAT compared to standard hospital care for children with 
moderate/severe cellulitis, it is possible that the single centre trial and artificial environments 
may limit the generalisability and external validity of the findings. It is recommended that 
additional studies are undertaken in other settings to determine the cost-effectiveness of 
OPAT for children with moderate/severe cellulitis.   
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